Allergy vaccine development

Peanut allergy is the most common cause of food-induced anaphylactic reactions in Australia. Current clinical practice advice dietary avoidance to prevent fatal anaphylactic responses.

We are evaluating the use of an immunomodulatory vaccine developed using a novel and safe vaccine platform technology, to re-write the immune response to peanut antigens, from an allergic to a tolerant phenotype, with an emphasis on safety and induction of persistent state of non-reactivity to peanut.

This aims to reduce the burden on parents and care-givers to monitor dietary intake, enable children to engage socially without fear and reduce the number of emergency presentations.